Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021
Cash & Equivalents	75.14	0.19	56.76
Short-Term Investments	19.76	32.19	0
Cash & Cash Equivalents	94.9	32.37	56.76
Cash Growth	193.15%	-42.96%	-
Other Current Assets	1.75	0.42	1.91
Total Current Assets	96.65	32.79	58.66
Property, Plant & Equipment	0.07	0.21	0.34
Other Long-Term Assets	0	0.03	0.03
Total Long-Term Assets	0.07	0.24	0.37
Total Assets	96.72	33.03	59.03
Accounts Payable	0.19	1.13	0.76
Current Debt	0.07	0.13	0.12
Other Current Liabilities	5.4	4.02	1.56
Total Current Liabilities	5.65	5.28	2.44
Long-Term Debt	0	0.08	0.22
Other Long-Term Liabilities	0	0	0.01
Total Long-Term Liabilities	0	0.08	0.23
Total Liabilities	5.65	5.36	2.67
Total Debt	0.07	0.21	0.35
Debt Growth	-69.19%	-39.37%	-
Retained Earnings	-249.74	-221.87	-191.37
Comprehensive Income	0.03	-0.08	0
Shareholders' Equity	91.07	-186.95	-158.26
Net Cash / Debt	94.83	32.16	56.41
Net Cash / Debt Growth	194.87%	-42.99%	-
Net Cash Per Share	9.07	174.20	5.79
Working Capital	90.99	27.51	56.22
Book Value Per Share	8.71	-1012.63	-16.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).